Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.

Glypican 3 (GPC3) is a valuable diagnostic marker and a potential therapeutic target in hepatocellular carcinoma (HCC). To evaluate the efficacy of targeting GPC3 at the translational level, we used RNA interference to examine the biologic and molecular effects of GPC3 suppression in HCC cells in vitro and in vivo. Transfection of Huh7 and HepG2 cells with GPC3-specific small interfering RNA (siRNA) inhibited cell proliferation (P < .001) together with cell cycle arrest at the G(1) phase, down-regulation of antiapoptotic protein (Bcl-2, Bcl-xL, and Mcl-1), and replicative senescence. Gene expression analysis revealed that GPC3 suppression significantly correlated with transforming growth factor beta receptor (TGFBR) pathway (P = 4.57e-5) and upregulated TGF-β2 at both RNA and protein levels. The effects of GPC3 suppression by siRNA can be recapitulated by addition of human recombinant TGF-β2 to HCC cells in culture, suggesting the possible involvement of TGF-β2 in growth inhibition of HCC cells. Cotransfection of siRNA-GPC3 with siRNA-TGF-β2 partially attenuated the effects of GPC3 suppression on cell proliferation, cell cycle progression, apoptosis, and replicative senescence, confirming the involvement of TGF-β2 in siRNA-GPC3-mediated growth suppression. In vivo, GPC3 suppression significantly inhibited the growth of orthotopic xenografts of Huh7 and HepG2 cells (P < .05), accompanied by increased TGF-β2 expression, reduced cell proliferation (observed by proliferating cell nuclear antigen staining), and enhanced apoptosis (by TUNEL staining). In conclusion, molecular targeting of GPC3 at the translational level offers an effective option for the clinical management of GPC3-positive HCC patients.

[1]  D. Schlessinger,et al.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome , 1996, Nature Genetics.

[2]  H. Aburatani,et al.  Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. , 2008, Cancer research.

[3]  S. Paul,et al.  Wnt signaling and cancer development: therapeutic implication. , 2008, Neoplasma.

[4]  Yutaka Takigawa,et al.  Wnt signaling in liver cancer. , 2008, Current drug targets.

[5]  S. Ishikawa,et al.  Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling , 2003, International journal of cancer.

[6]  S. Senju,et al.  Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma , 2006, Clinical Cancer Research.

[7]  J. Testa,et al.  OCI-5/GPC3, a Glypican Encoded by a Gene That Is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line–specific Manner , 1998, The Journal of cell biology.

[8]  M. Ozturk,et al.  Transforming growth factor‐beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth , 2010, Hepatology.

[9]  C. Lobe,et al.  Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. , 2005, Cancer research.

[10]  Rui Li,et al.  An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma , 2005, Oncogene.

[11]  J. Filmus,et al.  Glypican-3 and Alphafetoprotein as Diagnostic Tests for Hepatocellular Carcinoma , 2012, Molecular Diagnosis.

[12]  Hiroyuki Yamamoto,et al.  Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. , 2010, World journal of gastroenterology.

[13]  J. Filmus,et al.  Glypicans in growth control and cancer. , 2001, Glycobiology.

[14]  R. Tsien,et al.  Imaging Tri-Fusion Multimodality Reporter Gene Expression in Living Subjects , 2004, Cancer Research.

[15]  J. Filmus,et al.  Identification of a new membrane-bound heparan sulphate proteoglycan. , 1995, The Biochemical journal.

[16]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[17]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[18]  P. Hayashi,et al.  The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. , 2006, The Medical clinics of North America.

[19]  J. Filmus,et al.  Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo , 2008, International journal of cancer.

[20]  C. McKerlie,et al.  Glypican-3–Deficient Mice Exhibit Developmental Overgrowth and Some of the Abnormalities Typical of Simpson-Golabi-Behmel Syndrome , 1999, The Journal of cell biology.

[21]  V. Paradis,et al.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. , 2006, Human pathology.

[22]  J. Filmus,et al.  The Loss of Glypican-3 Induces Alterations in Wnt Signaling* , 2005, Journal of Biological Chemistry.

[23]  G. Giannelli,et al.  Inhibiting TGF-β signaling in hepatocellular carcinoma. , 2011, Biochimica et biophysica acta.

[24]  S. Thorgeirsson,et al.  Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma , 2008, Hepatology.

[25]  H. Hsu,et al.  Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway , 2008, Carcinogenesis.

[26]  Hong-Yang Wang,et al.  Upregulation of Glypican‐3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[27]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[28]  Ping Xu,et al.  Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. , 2008, Developmental cell.

[29]  Rajagopal N. Aravalli,et al.  Molecular mechanisms of hepatocellular carcinoma , 2008, Hepatology.

[30]  K. Matsuzaki,et al.  Regulatory mechanisms for transforming growth factor β as an autocrine inhibitor in human hepatocellular carcinoma: Implications for roles of Smads in its growth , 2000, Hepatology.

[31]  H. Aburatani,et al.  Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma , 2004, Cancer Research.

[32]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[33]  S. Fan,et al.  Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. , 2008, Carcinogenesis.

[34]  S. Fan,et al.  Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years , 2001, Annals of surgery.

[35]  S. Jeon,et al.  Both ERK and Wnt/β-catenin pathways are involved in Wnt3a-induced proliferation , 2005, Journal of Cell Science.

[36]  T. Roskams,et al.  Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules , 2006, The American journal of surgical pathology.

[37]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[38]  L. Terracciano,et al.  Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. , 2008, American journal of clinical pathology.

[39]  R. Cartun,et al.  Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study , 2008, Modern Pathology.

[40]  J. Filmus,et al.  The role of glypican-3 in the regulation of body size and cancer , 2008, Cell cycle.